[ad_1]
“An unprecedented anti-Covid vaccination campaign is about to start in Italy,” announces Minister Roberto Speranza. The first doses, scheduled for the end of January, are for the most exposed categories: health professions, fragile subjects, elderly with pathologies, guests and RSA operators. Of course, we will still have to be very careful, there is an invisible enemy ready to attack. But the vaccine promises to be effective and safe. We talked about it with Nicola Magrini, director general of the Italian drug agency (Aifa), who responds to Professor Crisanti, the infectious diseases specialist from Padua about the reliability of the operation with the data of the imminent mass immunization. “We will start gradually – declares Magrini from the Internazionale conference -. One, two, then three million a month …
He is about to go to Italy “one anti Covid vaccination campaign unprecedented “, announces the minister Roberto Speranza. The first doses, scheduled for the end of January, are for the most exposed categories: health professionals, fragile subjects, elderly people with pathologies, guests and RSA operators. Of course, we will still have to be very careful, there is an invisible enemy ready to attack. But the vaccine promises to be effective and safe. We talk about it with Nicola Magrini, general manager ofItalian Medicines Agency (Aifa), who responds to Professor Crisanti, the specialist in infectious diseases from Padua, doubtful about the reliability of the operation, with the data of the imminent mass immunization. “We will start gradually – says Magrini from the Internazionale conference -. One, two, then three million a month of different vaccines, which will be kept strictly separate, the important thing will always be to do the booster with the same type ”.
Covid Newsletter: data as of November 22
Director, can you explain why the incoming vaccine is safe?
“Because all the validation and evaluation phases are respected, no steps have been skipped. The last and most important, phase 3, involved randomized studies in tens of thousands of people, much more than those carried out, for example, for pertussis, to evaluate the protective effects and the ability to prevent Covid-19 infection “.
Doctors are preparing to administer millions of doses produced by Pfizer, Moderna and Astrazeneca, but the instruction booklet, so to speak, has yet to be printed. Not missing a ticket?
“The files will be submitted to the European Regulatory Authority for approval in December, but we already know their potential, they have extensive studies behind them. In these months 30-40 thousand, even 60 thousand volunteers, have been tested for safety against adverse events rare has been widely verified. “
But could the rush to get there lead to underestimating something?
“I exclude it because these events, on the order of one in a thousand, occur in an observation time of at least 8 weeks, if any, they would have been seen, and late effects are very rare. They are vaccines studied according to standards intended for registration. It is out of place to think that things have been done quickly and badly. Pfizer and Moderna have already announced their results, Astrazeneca will do so in early December, and it is not a race to finish first, they are concomitant solutions ”.
So would you assume that all three competitors will pass the test?
We don’t take anything for granted here. I say we have more detailed summary data than perhaps makes it to the media, and the dossiers have yet to pass the scrutiny of the regulatory authorities. A process that this time, given the situation, will not take months. . I add that we have often been involved in continuous reviews, we have followed the experiments step by step. “
How was it possible then to move on?
“There has been an international mobilization never seen before, an exchange of information that opens up unimaginable scenarios, research institutes from around the world have launched into the company by deploying the most advanced technologies and leading scientists. Vaccines are on the way. which can boast of a high immune response. “
In the fight against the Sars-Cov-2 virus, have you considered the possibility that once the vaccines arrive in January, there will be candidates who drop out?
We estimate that in the first and second trimesters of next year, adherence to the vaccination offered to risk subjects will be much higher than 75%. When we move on to mass vaccination, adherence should still exceed 70%. We will respond to the No Vaxes’ doubts with active pharmacovigilance studies, and a vaccinated app, but without forcing anyone ”.
Will we be able to stop bothering with masks, spacing and closures once we are vaccinated?
“Later, certain precautions will also be necessary, in accordance with social norms, if only to prevent new infections, such as seasonal flu.”
© All rights reserved
